Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 1;4(8):1123-1124.
doi: 10.1001/jamaoncol.2017.3993.

Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation

Allison M Martin  1 , Daniel N Cagney  1 , Paul J Catalano  2   3 , Brian M Alexander  1 , Amanda J Redig  4 , Jon D Schoenfeld  1 , Ayal A Aizer  1
Affiliations

Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation

Allison M Martin et al. JAMA Oncol. .

Abstract

This study investigates the association between immunotherapy and symptomatic radiation necrosis in patients with melanoma, non–small-cell lung cancer, or renal cell carcinoma and newly diagnosed brain metastases treated with stereotactic radiation therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Redig reports consulting fees from Medtronic, Boehringer-Ingelheim, and Proactive Worldwide Inc. Dr Schoenfeld reports consulting and scientific advisory board fees for BMS, AstraZeneca, Nanobiotix, Tilos, Debiopharm as well as research funding from Merck and BMS. Dr Aizer reports research funding from Varian Medical Systems. No other conflicts are reported.

Figures

Figure.
Figure.. Kaplan-Meier Curves Displaying Freedom From Symptomatic Necrosis as Stratified by Receipt of Immunotherapy vs No Receipt of Immunotherapy
Log rank P<.001.
See this image and copyright information in PMC

Comment in

References

    1. Giglio P, Gilbert MR. Cerebral radiation necrosis. Neurologist. 2003;9(4):180-188. - PubMed
    1. Chasset F, Pages C, Biard L, et al. Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids. Eur J Dermatol. 2015;25(1):36-44. - PubMed
    1. Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976-983. - PMC - PubMed
    1. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459-465. - PubMed
    1. Tawbi HA-H, Forsyth PAJ, Algazi AP, et al. Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the phase II study CheckMate 204. J Clin Oncol. 2017;35(suppl 15):9507-9507.

MeSH terms